Enhancement of fibrin binding and activation of plasminogen by staplabin through induction of a conformational change in plasminogen  by Takayasu, Ritsuko et al.
FEBS Letters 418 (1997) 58-62 FEBS 19482 
Enhancement of fibrin binding and activation of plasminogen by 
staplabin through induction of a conformational change in plasminogen 
Ritsuko Takayasu, Keiji Hasumi*, Chikara Shinohara, Akira Endo 
Department of Applied Biological Science, Tokyo Noko University, 3-5-8 Saiwaicho, Fuchu, Tokyo 183, Japan 
Received 13 August 1997; revised version received 14 October 1997 
Abstract Staplabin (0.3-0.6 mM), a fungal triprenyl phenol, 
enhanced 3-6-fold the plasminogen activator-catalyzed activa-
tion of Glu-plasminogen and Lys-plasminogen as well as their 
binding to fibrin. Staplabin was not stimulatory to the amidolytic 
activity of plasmin and plasminogen activators. Even in the 
presence of e-aminocaproic acid (EACA) and fibrinogen frag-
ments, allosteric effectors for Glu-plasminogen, staplabin 
increased the activation of both forms of plasminogen. In size-
exclusion chromatography of Glu-plasminogen and Lys-plasmi-
nogen, the molecular elution time, which varies as the 
conformation of a protein changes, was shortened by staplabin. 
These results suggest that staplabin causes plasminogens to be 
more susceptible to activation and fibrin binding by inducing a 
conformational change that is, at least in part, different from 
that induced by EACA and fibrinogen fragments. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The plasminogen/plasmin system is involved in a variety of 
physiological and pathological processes requiring localized 
proteolysis, such as fibrinolysis, inflammation, tissue remodel-
ing, ovulation, tumor metastasis and tissue invasion of patho-
gens [1-5]. Native plasmmogen (Pig) with NH 2 - terminal Glu
1 
(Glu-Plg) is a single-chain glycoprotein with multiple func-
tional domains, which consist of an NH 2 - terminal peptide 
(NTP), five homologous kringle domains and a trypsin-like 
serine protease domain [6,7]. Plasmic hydrolysis of Glu-Plg 
yields a truncated form of Pig called Lys-Plg, which predom-
inantly has Lys78 as an NH 2 - terminal residue [8,9]. Glu-Plg 
exhibits a tight spiral structure bringing the N T P into close 
contact with the protease domain [10]. The tight conformation 
of Glu-Plg is postulated to be the result of an intramolecular 
interaction between a lysine residue in the N T P and the ami-
nohexyl site of kringle 5 (K5) in Glu-Plg [11,12]. Lys-Plg, 
which lacks N T P , adopts a more relaxed and extended con-
formation than does Glu-Plg [12,13]. 
The binding of Pig to fibrin and cell surfaces localizes fibri-
nolytic activity on these surfaces [14]. These Pig bindings are 
mediated via lysine binding sites (or aminohexyl sites) located 
"Corresponding author. Fax: (81) (423) 34 4661. 
E-mail: hasumi@cc.tuat.ac.jp 
Abbreviations: Pig, plasminogen; EACA, e-aminocaproic acid; NTP, 
NH2-terminal peptide; u-PA, urokinase-type plasminogen activator; 
t-PA, tissue-type plasminogen activator; pNA, /j-nitroaniline; CNBr-
Fbg, CNBr fragment of fibrinogen; PAGE, polyacrylamide gel 
electrophoresis 
within the kringle domains [15,16]. The tight conformation of 
Glu-Plg attenuates the interaction of the kringle with fibrin 
and cellular receptors, resulting in a low affinity binding of 
Glu-Plg to these substrates [17-19]. Lysine analogs, such as e-
aminocaproic acid (EACA), inhibit Pig binding by competing 
with fibrin or cell surface receptors for the lysine binding sites. 
On the other hand, binding of lysine analogs to the low af-
finity lysine binding sites in K5 and K4 (first in K5, then K4) 
of Glu-Plg induces a large-scale conformational change in 
Glu-Plg [12,20,21], facilitating its activation to plasmin by 
Pig activators. A similar conformational change occurs upon 
binding of Glu-Plg to fibrin [17,22]. 
We have recently found a novel fungal triprenyl phenol 
metabolite (designated staplabin) as an activator of the bind-
ing of Glu-Plg to fibrin and monocytoid U937 cells [23]. This 
study was undertaken to explore the mechanism of the sta-
plabin enhancement of Pig binding. As a result, evidence sug-
gests that staplabin induced a conformational change in both 
Glu-Plg and Lys-Plg to allow them to bind fibrin and to be 
activated by Pig activators with greater efficiency. These ef-
fects of staplabin are quite different from the effects of lysine 
analogs, which also relax Pig conformation and accelerate Pig 
activation but inhibit fibrin binding of Pig. 
2. Materials and methods 
2.1. Materials 
Glu-Plg and Lys-Plg were from Enzyme Research Laboratories 
(South Bend, IN, USA). Two-chain urokinase-type Pig activator (u-
PA) was purchased from JCR Pharmaceuticals (Kobe, Japan) and 
two-chain tissue-type Pig activator (t-PA) from American Diagnostica 
(Greenwich, CT, USA). Aprotinin was from CosmoBio (Tokyo, Ja-
pan). EACA, fibrinogen, thrombin, plasmin and S-2251 (H-D-Val-
Leu-Lys-p-NA) were from Sigma (St. Louis, MO, USA). Flavigen 
t-PA (CH3S02-D-HHT-Gly-Arg-p-NA) was obtained from Biopool 
(Umea, Sweden) and glutaryl-Gly-Arg-7-amino-4-methylcoumarin 
(Glt-Gly-Arg-AMC) from Cambridge Research Biochemicals (Chesh-
ire, UK). Na125I was purchased from Amersham. Staplabin 
(C28H39NO0; MW 485) was isolated from cultures of Stachybotrys 
microspora IFO 30018 as described previously [23]. Briefly, 1 1 of 
the culture supernatant was extracted with 1-butanol. The resulting 
organic extracts were subjected to successive chromatographic frac-
tionation using silica gel, Sephadex LH-20, and silica Cis columns, 
giving 24 mg of purified staplabin. The CNBr fragment of fibrinogen 
(CNBr-Fbg) was prepared as described [24,25]. Radioiodination of 
Glu-Plg, Lys-Plg and ovalbumin was performed using the chlor-
amine-T method [26]. The compositions of buffers were: buffer A, 
20 mM sodium phosphate and 150 mM NaCl, pH 7.4; buffer B, 
Hanks' balanced salt solution containing 1 mg/ml bovine serum albu-
min and 50 mM HEPES, pH 7.4; buffer C, 50 mM Tris-HCl, 100 mM 
NaCl and 0.01% Tween 80, pH 7.4; buffer D, 3.6% (w/v) SDS, 3.6% 
(w/v) 2-mercaptoethanol, 0.08% (w/v) bromophenol blue. 
2.2. Determination of ls5I-Plg binding to fibrin 
The assay was performed as described previously [23,27]. Briefly, a 
100-jj.l solution of human fibrinogen (0.2 mg/ml) in buffer A was 
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dispensed into each well of a 96-well plastic tissue culture plate. After 
drying the well by incubating at 37°C for 3-5 days, each well received 
75 ul of human thrombin (0.68 IU/ml in buffer A) and the plates were 
incubated at 37°C for 3 h. Fibrin clots formed in the wells were 
washed 3 times with 100 u.1 of buffer A, then incubated at 37°C for 
60 min with 50 ill of buffer B containing 50 nM 125I-Plg in the pres-
ence or absence of 0.2 M EACA. After washing the wells with buffer 
A (twice with 200 uj, then once with 100 uj), bound 126I-Plg was 
dissolved in 50 ul of 0.2 M NaOH and 2% (w/v) SDS at 37°C for 
30 min. A portion (40 ill) of the lysate was removed and counted for 
radioactivity using a y-counter. 
2.3. Determination of Pig activation by t-PA and u-PA 
Pig activation was assayed either by measuring the initial velocity of 
plasmin generation using a chromogenic substrate for plasmin or by 
determining the rate of conversion of 125I-Plg to 125I-plasmin using 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE). In the former 
assay, 0.1 uM Pig and 0.1 mM S-2251 were incubated in buffer C with 
either t-PA (1 U/ml) or u-PA (1 U/ml) at 37°C for up to 120 min. 
From the slope of the plots of ^405 nm versus i1 [28], the initial 
velocity of plasmin generation was calculated. In the latter assay, 
0.1 |iM 125I-Plg was incubated with t-PA (300 U/ml for incubation 
with 125I-Glu-Plg and 100 U/ml for 125I-Lys-Plg) and aprotinin (1000 
kallikrein inhibitory units/ml) in 30 u,l of buffer C. Aprotinin was used 
to inhibit plasmin activity that forms Lys-Plg during incubation of 
Glu-Plg [29]. After incubation at 37°C for 120 min, the mixture re-
ceived 9 mg of solid urea and 10 ui of buffer D, and then was heated 
at 90°C for 2 min. A portion (10 uj) of the mixture was subjected to 
SDS-PAGE [30] on a 10% gel. After fixing and drying, the gel was 
exposed to X-ray film at —80°C for 16 h. Radioactive bands corre-
sponding to Pig and the light and heavy chains of plasmin were 
excised from the gel and counted for radioactivity in a y-counter. 
2.4. Determination of amidolytic activities of plasmin, t-PA and u-PA 
The amidolytic activities of plasmin, t-PA and u-PA were deter-
mined in 100 ul of buffer C using S-2251, Flavigen t-PA or Glt-
Gly-Arg-AMC, respectively, as a substrate. The release of ^NA (for 
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Fig. 1. Enhancement of fibrin binding of 125I-Plg by staplabin. The 
binding of 125I-Glu-Plg (A) and 125I-Lys-Plg (B) to fibrin was deter-
mined in the presence of the indicated concentrations of staplabin. 
Where indicated, EACA (0.2 M) was included in the reaction mix-
ture. The specific activities of Pig used were 1.98 X 104 cpm/pmol for 
125I-Glu-Plg and 2.48 XlO4 cpm/pmol for 125I-Lys-Plg. Each value 
represents the mean±S.D. from triplicate determinations. 
Staplabin (mM) 
Fig. 2. Enhancement by staplabin of t-PA-catalyzed generation of 
plasmin activity from Pig. The activation of Glu-Plg (■) and Lys-
Plg (□) was determined by measuring the generation of plasmin ac-
tivity in the presence of the indicated concentrations of staplabin. 
Each value represents the mean±S.D. from triplicate determina-
tions. The control values for Glu-Plg and Lys-Plg were 0.10 ±0.004 
and 0.74 ±0.003 nmol ^NA/well/h2, respectively. 
S-2251 and Flavigen t-PA) or 7-amino-4-methylcoumarin (for Glt-
Gly-Arg-AMC) was measured as an absorbance at 405 nm using a 
model 450 microplate reader or as fluorescence intensity at an excita-
tion wavelength of 380 nm and an emission at 480 nm using a model 
650 fluorescence spectrometer (Hitachi), respectively. The enzyme and 
substrate concentrations were: 10 nM and 0.1 mM for plasmin; 5 U/ 
ml and 0.1 mM for both t-PA and u-PA. 
2.5. Size-exclusion HPLC 
Ten microliters of 0.1 u,M 125I-Plg or 125I-ovalbumin (a control for 
non-allosteric protein) in buffer C were applied to a TSKgel 
G3000SW column (0.75x60 cm; TOSO Co., Japan) equilibrated 
with buffer C or buffer C containing 0.4 or 0.6 mM staplabin. The 
column was developed with the same buffer at a rate of 1 ml/min at 
22°C. The eluate fraction (0.33 ml) was counted for radioactivity in a 
y-counter. 
3. Results 
Lys-Plg, which has an extended, relaxed molecular struc-
ture, is known to bind to fibrin more efficiently than Glu-
Plg, which adopts a closed, tight conformation [17,18]. In 
the present experiments, the level of fibrin binding of 125I-
Lys-Plg is 4 times higher than that of 125I-Glu-Plg (Fig. 1). 
As described previously, staplabin enhanced 125I-Glu-Plg 
binding to fibrin 2.5^-fold at concentrations ranging from 
0.4 to 0.6 mM (Fig. 1A). The binding of 125I-Lys-Plg was 
similarly increased by staplabin at the same concentrations 
(Fig. IB). In both cases, the binding was inhibited 74-93% 
by EACA, suggesting that the binding in the presence of sta-
plabin involved lysine binding sites of Pig. 
Since a Pig molecule with a relaxed conformation is effi-
ciently activated by t-PA and u-PA, we tested whether stapla-
bin enhances Pig activation by these Pig activators. When 
measured as an increase in plasmin amidolytic activity, the 
rate of t-PA-catalyzed activation of Lys-Plg was seven times 
as high as that of Glu-Plg. The activation of both Glu-Plg and 
Lys-Plg by t-PA was significantly enhanced by staplabin (3-
6.8-fold at 0.3-0.6 mM; Fig. 2). Similar results were obtained 
when u-PA was used as a Pig activator (data not shown). In 
control incubations in the absence of Pig activators, staplabin 
showed no effect on the hydrolysis of S-2251 by Pig. Staplabin 
was stimulatory to neither plasmin, t-PA nor u-PA (data not 
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Fig. 3. Enhancement by staplabin of t-PA-catalyzed conversion of 125I-Plg to 125I-plasmin. The t-PA-catalyzed conversion of 125I-Glu-Plg (A) 
and 125I-Lys-Plg (B) to 125I-plasmin was determined in the presence of the indicated concentrations of staplabin. The specific activities of Pig 
used were 1.01 X104 cpm/pmol for 125I-Glu-Plg and 1.26X104 cpm/pmol for 125I-Lys-Plg. Top: Representative autoradiograms (H, heavy 
chain; L, light chain). Bottom: The rate of conversion, which was calculated by dividing the radioactivity of plasmin (heavy chain plus light 
chain) by the radioactivity of Pig plus plasmin. Each value represents the mean ± S.D. from triplicate determinations. 
shown). To test whether these increases in the generation of 
plasmin activity accompanied the formation of a two-chain 
form, 125I-Plg incubated with Pig activators in the presence 
of aprotinin was analyzed by SDS-PAGE under reducing con-
ditions. As shown in Fig. 3, the rate of t-PA-catalyzed con-
version of 125I-Glu-Plg to 125I-Glu-plasmin was ~ 5% in con-
trol incubations, while the rate was significantly increased by 
staplabin (to 57-84% at 0.4-0.6 mM). Similarly, a significant 
increase in the conversion of 125I-Lys-Plg to 125I-plasmin 
(from 32 to 79%) was observed in the presence of 0.4 mM 
staplabin. 
Table 1 
Reversibility of the effect of staplabin on Glu-Plg activation by t-
PA 
Staplabin (mM) 
At prein-
cubation 
0 
0 
0 
0.6 
0.6 
At activation 
assay 
0 
0.02 
0.60 
0.02 
0.60 
Generation of plasmin activity 
(nmol /)NA/well/h2) 
0.07710.004 
0.081 ±0.001 
0.171 ±0.003 
0.080 ±0.003 
0.171 ±0.004 
Glu-Plg (3 uM) was preincubated at 37°C for 20 min in the presence 
of the indicated concentrations of staplabin. Subsequently, a portion 
of the mixture was removed and diluted 30-fold (so that the concen-
tration of Glu-Plg became 0.1 iiM) and assayed for Pig activation by 
t-PA (1 unit/ml) at 37°C in the presence of the indicated concentra-
tions of staplabin. 
Next, the reversibility of the staplabin effect was examined. 
Glu-Plg was preincubated at 37°C for 20 min with or without 
staplabin (0.6 mM). Subsequently, the mixture was diluted to 
assay Pig activation by t-PA at staplabin concentrations of 
0.03 and 0.6 mM. Regardless of the preincubation with sta-
plabin, Glu-Plg activation was significantly enhanced only 
when a sufficient concentration of staplabin was present dur-
ing the activation incubation, demonstrating that the effect of 
staplabin was reversible (Table 1). 
CNBr-Fbg and EACA induce a large-scale conformational 
change in the Glu-Plg molecule. These effectors enhanced 
u-PA-catalyzed activation of Glu-Plg severalfold. When sta-
plabin was present, the effects of CNBr-Fbg and EACA on 
u-PA-catalyzed Glu-Plg activation were less prominent (Fig. 
4). However, the level of activation was still higher in the 
presence of both staplabin and CNBr-Fbg (or EACA) than 
in the presence of CNBr-Fbg (or EACA) alone. On the other 
hand, CNBr-Fbg and EACA caused little change in Lys-Plg 
activation. Staplabin was also active in enhancing Lys-Plg 
activation in the presence of these effectors (Fig. 4). 
To test whether staplabin induces a conformational change 
in the Pig molecule, 125I-Glu-Plg and 125I-Lys-Plg were ana-
lyzed by size-exclusion HPLC both in the absence and in the 
presence of staplabin (Fig. 5). By adding staplabin to the 
elution buffer, the molecular elution time for 125I-Glu-Plg 
was changed from 17.0 to 16.3 min. Similarly, the elution 
time for 125I-Lys-Plg was changed from 16.7 to 16.3 min by 
staplabin. Since the changes in the elution time were too small 
to account for molecular aggregation of Pigs, these results 
should represent a structural alteration from a smaller to a 
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Fig. 4. Effects of CNBr-Fbg and EACA on Pig activation by u-PA in the absence and presence of staplabin. The u-PA-catalyzed generation of 
plasmin activity from Glu-Plg (A, C) and Lys-Plg (B, D) was assayed in the presence of the indicated concentrations of CNBr-Fbg (A, B) or 
EACA (C, D). Where indicated (□), the reaction mixture contained 0.6 mM (for Glu-Plg) or 0.4 mM (for Lys-Plg) staplabin. Each value repre-
sents the mean±S.D. from triplicate determinations. 
larger molecular shape. No changes in elution time were ob-
served for 125I-ovalbumin, which was used as a non-allosteric 
protein control [12] (data not shown). 
4. Discussion 
The present results demonstrate that staplabin enhances 
both fibrin binding and t-PA- and u-PA-catalyzed activation 
of both Glu-Plg and Lys-Plg. Changes in conformation of the 
Pig molecule, from a tight, spiral form to a relaxed, extended 
one, accompany both an increase in the activation and fibrin 
binding of Pig [17,18,31,32]. The fact that the molecular elu-
tion time for Glu-Plg and Lys-Plg in size-exclusion HPLC is 
shortened by the presence of staplabin suggests that staplabin 
causes Pig molecules to adopt more relaxed conformations 
[12]. In the presence of two allosteric effectors for Glu-Plg, 
EACA and CNBr-Fbg, staplabin is still active in enhancing 
Glu-Plg activation. In addition, the activation of Lys-Plg, 
which has an extended, relaxed structure due to the absence 
of the intramolecular interaction between a lysine residue in 
NTP and K5 [11,12], is not enhanced by EACA and CNBr-
Fbg but it is by staplabin. Thus, the staplabin-induced con-
formational change in Pig may not be similar to that induced 
by dissociation of the intramolecular interaction. Supporting 
this hypothesis is the observation that u-PA-catalyzed activa-
tion of mini-Pig, which lacks NTP and K1-K4, is also ele-
vated by staplabin (data not shown). This finding further 
suggests that a disruption of the interaction between K4 and 
the tetranectin-like sequence in K3, which is postulated to 
participate in maintaining the [3-conformation of Lys-Plg 
[12], is not a mechanism for the action of staplabin. The fibrin 
binding of Pigs is inhibited by an excess of EACA or several 
other ligands of lysine binding sites in the kringle. In contrast 
to these ligands, staplabin increases Pig-fibrin binding, and the 
staplabin-enhanced binding is inhibited by EACA. These ob-
servations suggest that lysine binding sites in the kringle do 
not play a role in the conformational change induced by sta-
plabin. Taken together, the present results suggest that stapla-
bin causes Pigs to be more susceptible to activation and fibrin 
binding by inducing a conformational change that is, at least 
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Fig. 5. Size-exclusion HPLC elution profile of 125I-Plg in the ab-
sence and presence of staplabin. 125I-Glu-Plg (A) or 125I-Lys-Plg (B) 
(2.5 pmol each) was analyzed by size-exclusion HPLC in the ab-
sence (o) or presence (•) of staplabm (0.6 mM for Glu-Plg and 0.4 
mM for Lys-Plg). The specific activities of Pig used were 6.95 XlO3 
cpm/pmol for 125I-Glu-Plg and 8.92 x 103 cpm/pmol for 125I-Lys-Plg. 
Each value represents the average of duplicate determinations. 
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in part , different from that induced by E A C A and CNBr-Fbg. 
At higher concentrations of staplabin, the stimulatory effect 
on Pig binding to fibrin as well as on Pig activation declines. 
While the detailed mechanism is currently unknown, it may be 
related to the extent of the conformational change of Pig. 
It would be interesting to ask whether staplabin-induced 
changes in Pig conformation result in an increase in binding 
of Pig to streptokinase [33]. In preliminary experiments, sta-
plabin was found to enhance streptokinase-mediated activa-
tion of Glu-Plg. Although this effect appears to be due to an 
acceleration of complex formation between streptokinase and 
Glu-Plg, details are to be examined in future studies. 
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